When it comes to low‐risk patients with CBF‐AML (RUNX1‐RUNX1T1 or CBFβ/MYH11), none (0/4) of them in CLAG‐M experienced PD or death, while up to 50% (3/6) of patients received MEC/IEC suffered PD within 6 month, and all of them died eventually. This evidence concerns the gene RUNX1T1 and acute myeloid leukemia.